NEKTAR THERAPEUTICS Business Summary

Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, collaboration milestones, and royalty streams from its proprietary polymer conjugate and PEGylation technology platforms. The company’s business is segmented into two primary therapeutic areas: Immunology, led by its flagship regulatory T-cell (Treg) agonist rezpegaldesleukin (REZPEG) for atopic dermatitis and alopecia areata, and Oncology, featuring NKTR-255, an IL-15 receptor agonist designed to enhance natural killer cell activity. Following the 2024 sale of its Huntsville manufacturing facility, Nektar has transitioned to a capital-efficient model focused on late-stage clinical development, recently securing a $300 million public offering in February 2026 to fund Phase 3 trials. Direct competitors include Incyte, Exelixis, Coherus BioSciences, and Moderna; Nektar distinguishes itself as a specialized immunotherapy player leveraging niche Treg-mediated pathways to address unmet needs in chronic inflammatory diseases. Nektar was founded in 1990 by John Stuart Patton, Ph.D., a pioneer in pulmonary drug delivery who remains a significant shareholder. The leadership team is headed by President and CEO Howard W. Robin, who joined in 2007 following a successful tenure as CEO of Sirna Therapeutics (acquired by Merck) and a 20-year career at Berlex Laboratories. Research and development are led by Chief R&D Officer Jonathan Zalevsky, Ph.D., an immunology expert formerly of Xencor, while financial operations are managed by CFO Gil M. Labrucherie. In early 2025, the company appointed Dr. Brian Kotzin, a former Amgen executive with four decades of immunology experience, as Interim Chief Medical Officer to oversee the pivotal REZOLVE-AD program. Notable institutional backing includes Deep Track Capital LP, which holds a dominant 90% stake as of early 2026, alongside long-term investors such as BB Biotech, Vanguard, and BlackRock.